Suppr超能文献

微生物群的治疗性调控:过去、现在及未来考量

Therapeutic manipulation of the microbiota: past, present, and considerations for the future.

作者信息

Young V B

机构信息

Department of Internal Medicine/Infectious Diseases Division, Department of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.

出版信息

Clin Microbiol Infect. 2016 Nov;22(11):905-909. doi: 10.1016/j.cmi.2016.09.001. Epub 2016 Sep 10.

Abstract

BACKGROUND

The growing appreciation of the potential role of indigenous microbiota in disease has resulted in a concomitant interest in manipulating the microbiome for therapeutic effect. The most successful example of microbiota manipulation for treatment of a disease is in recurrent infection with the bacterial pathogen Clostridium difficile.

AIMS

This review provides historic perspectives on development of microbiota transplantation and reviews evidence for its use in recurrent C. difficile infection.

SOURCES

A PubMed search of the terms ([fecal transplant OR fecal transplantation] AND difficile) to 9 June 2016 yielded 415 articles.

CONTENT

Recent work has pointed to potential mechanisms by which microbiota restoration in the form of faecal transplantation has been efficacious. This includes studies of microorganisms associated with successful faecal transplantation in human and animal studies and a focus on bacterial bile acid metabolism as a mechanism that mediates colonization resistance against the pathogen. The potential use of microbiota manipulation for other diseases such as inflammatory bowel diseases and metabolic disorders will be discussed. The case will be made that the lessons learned from treatment of recurrent C. difficile infection may not necessarily translate to use of faecal transplantation or other methods to alter the microbiome for the treatment of other diseases.

IMPLICATIONS

A key conclusion that can be drawn is that understanding of the precise role of the microbiota in the pathogenesis of a specific disease is necessary prior to determining if microbiota manipulation represents a novel treatment therapy.

摘要

背景

对本土微生物群在疾病中潜在作用的认识不断增加,相应地人们也对通过操纵微生物组来产生治疗效果产生了兴趣。微生物群操纵治疗疾病最成功的例子是用于治疗细菌性病原体艰难梭菌的复发性感染。

目的

本综述提供了微生物群移植发展的历史观点,并综述了其用于复发性艰难梭菌感染的证据。

资料来源

截至2016年6月9日,在PubMed上搜索关键词([粪便移植或粪菌移植]和艰难梭菌),共获得415篇文章。

内容

最近的研究指出了粪菌移植形式的微生物群恢复有效的潜在机制。这包括在人类和动物研究中对与成功粪菌移植相关的微生物的研究,以及将重点放在细菌胆汁酸代谢作为介导对病原体定植抗性的一种机制上。还将讨论微生物群操纵在其他疾病如炎症性肠病和代谢紊乱中的潜在应用。有观点认为,从复发性艰难梭菌感染治疗中吸取的经验教训不一定能转化为使用粪菌移植或其他方法来改变微生物组以治疗其他疾病。

启示

可以得出的一个关键结论是,在确定微生物群操纵是否代表一种新的治疗方法之前,有必要了解微生物群在特定疾病发病机制中的精确作用。

相似文献

3
Fecal microbiota transplantation: past, present and future perspectives.粪便微生物群移植:过去、现在和未来展望
Minerva Gastroenterol Dietol. 2017 Dec;63(4):420-430. doi: 10.23736/S1121-421X.17.02374-1.
6
Fecal microbiota transplantation in children: a brief review.儿童粪便微生物群移植:简要综述
Pediatr Res. 2016 Jul;80(1):2-6. doi: 10.1038/pr.2016.48. Epub 2016 Mar 16.
7
Fecal Microbiota Transplantation.粪便微生物群移植
Gastroenterol Clin North Am. 2017 Mar;46(1):171-185. doi: 10.1016/j.gtc.2016.09.012.

引用本文的文献

3
Fecal Microbiota Transplantation: What's New?粪便微生物群移植:有哪些新进展?
Microorganisms. 2021 Dec 24;10(1):23. doi: 10.3390/microorganisms10010023.
4
Antibiotic Resistance: One Health One World Outlook.抗生素耐药性:同一健康,同一世界的展望。
Front Cell Infect Microbiol. 2021 Nov 25;11:771510. doi: 10.3389/fcimb.2021.771510. eCollection 2021.

本文引用的文献

1
Fecal Transplants: What Is Being Transferred?粪便移植:移植的是什么?
PLoS Biol. 2016 Jul 12;14(7):e1002503. doi: 10.1371/journal.pbio.1002503. eCollection 2016 Jul.
5
Fecal microbiota transplant for Clostridium difficile infection in older adults.老年人艰难梭菌感染的粪便微生物群移植
Therap Adv Gastroenterol. 2016 May;9(3):273-81. doi: 10.1177/1756283X15622600. Epub 2015 Dec 31.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验